ImmunoGen, Inc. (NASDAQ:IMGN) Shares Sold by Primecap Management Co. CA

Primecap Management Co. CA decreased its position in shares of ImmunoGen, Inc. (NASDAQ:IMGN) by 0.2% during the first quarter, according to its most recent filing with the SEC. The firm owned 3,757,600 shares of the biotechnology company’s stock after selling 7,400 shares during the period. Primecap Management Co. CA’s holdings in ImmunoGen were worth $10,183,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of IMGN. The Manufacturers Life Insurance Company lifted its stake in ImmunoGen by 9.6% in the first quarter. The Manufacturers Life Insurance Company now owns 97,205 shares of the biotechnology company’s stock worth $263,000 after purchasing an additional 8,527 shares during the last quarter. Commonwealth Equity Services LLC lifted its stake in ImmunoGen by 146.9% in the first quarter. Commonwealth Equity Services LLC now owns 35,729 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 21,259 shares during the last quarter. State of Wisconsin Investment Board lifted its stake in ImmunoGen by 39.5% in the first quarter. State of Wisconsin Investment Board now owns 206,700 shares of the biotechnology company’s stock worth $560,000 after purchasing an additional 58,500 shares during the last quarter. Jennison Associates LLC lifted its stake in ImmunoGen by 37.2% in the first quarter. Jennison Associates LLC now owns 1,471,676 shares of the biotechnology company’s stock worth $3,988,000 after purchasing an additional 398,855 shares during the last quarter. Finally, Swiss National Bank lifted its stake in ImmunoGen by 3.1% in the first quarter. Swiss National Bank now owns 271,700 shares of the biotechnology company’s stock worth $736,000 after purchasing an additional 8,200 shares during the last quarter. Hedge funds and other institutional investors own 79.29% of the company’s stock.

Several analysts have issued reports on the stock. Zacks Investment Research downgraded shares of ImmunoGen from a “buy” rating to a “hold” rating in a research note on Wednesday, May 8th. BidaskClub raised shares of ImmunoGen from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 4th. Piper Jaffray Companies lowered shares of ImmunoGen from an “overweight” rating to a “neutral” rating and reduced their target price for the stock from $13.00 to $2.50 in a research report on Friday, March 1st. Morgan Stanley raised shares of ImmunoGen from an “underweight” rating to an “equal weight” rating and set a $2.68 target price on the stock in a research report on Tuesday, March 5th. Finally, Jefferies Financial Group lowered shares of ImmunoGen from a “buy” rating to a “hold” rating in a research report on Friday, March 1st. Three analysts have rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the stock. ImmunoGen has a consensus rating of “Hold” and a consensus price target of $3.03.

Shares of NASDAQ:IMGN traded down $0.20 during trading on Friday, reaching $1.98. 3,535,502 shares of the company were exchanged, compared to its average volume of 2,889,256. The firm has a market cap of $325.98 million, a PE ratio of -1.68 and a beta of 2.24. ImmunoGen, Inc. has a 12-month low of $1.76 and a 12-month high of $12.31. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.72 and a current ratio of 4.72.

ImmunoGen (NASDAQ:IMGN) last issued its earnings results on Friday, May 3rd. The biotechnology company reported ($0.30) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.31) by $0.01. The business had revenue of $8.60 million for the quarter, compared to analyst estimates of $10.59 million. ImmunoGen had a negative net margin of 406.27% and a negative return on equity of 573.13%. The company’s quarterly revenue was down 56.6% compared to the same quarter last year. During the same period last year, the company posted ($0.30) earnings per share. Equities research analysts predict that ImmunoGen, Inc. will post -0.98 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “ImmunoGen, Inc. (NASDAQ:IMGN) Shares Sold by Primecap Management Co. CA” was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another site, it was illegally stolen and republished in violation of United States and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.com-unik.info/2019/06/15/immunogen-inc-nasdaqimgn-shares-sold-by-primecap-management-co-ca.html.

ImmunoGen Company Profile

ImmunoGen, Inc, a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm.

Featured Article: How to Profit and Limit Losses With Stop Orders

Want to see what other hedge funds are holding IMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ImmunoGen, Inc. (NASDAQ:IMGN).

Institutional Ownership by Quarter for ImmunoGen (NASDAQ:IMGN)

Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit